| abstract |
This invention describes a prodrug (I) of an ICE inhibitor that has good bioavailability. The compound of the formula (I) is useful for treating IL-1 mediated diseases, for example, rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, rejection of organ transplants, osteoarthritis, asthma, psoriasis, Alzheimer's disease, myocardial infarction, congestive heart failure, Huntington's disease, atherosclerosis, atopic dermatitis, leukemia and related disorders, myelodysplasia syndrome, uveitis or multiple myeloma. |